Roche buying Promedior for $390 million to develop drugs for fibrotic disease

first_img Jonathan Saltzman — Boston Globe Roche buying Promedior for $390 million to develop drugs for fibrotic disease Tags biotechnologyBostondrug developmentSTAT+ The Swiss drug giant Roche has agreed to pay $390 million upfront for a Lexington, Mass., biotech that has developed experimental drugs for fibrotic diseases, including a compound to treat a rare and fatal progressive lung disease.Roche is buying Promedior to obtain its entire medicine portfolio — including its lead drug candidate, which showed encouraging results in a midstage clinical trial to treat idiopathic pulmonary fibrosis, a lung disorder. SEBASTIEN BOZON/AFP/Getty Images STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. What is it? What’s included? Biotech GET STARTED By Jonathan Saltzman — Boston Globe Nov. 15, 2019 Reprints About the Author Reprints Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED Log In | Learn More last_img

Leave a Reply

Your email address will not be published. Required fields are marked *